Abstract:A tetranuclear Cu(II) complex of a pentadentate ligand, containing pyridine2,6‐diamide motif, is reported. The X‐ray structure of the complex reveals that it has an open book type architecture. The magnetic property of the complex is explored by VT susceptibility measurements and DFT calculations. The complex shows strong antiproliferative activity against HCT116 cancer cells. Possible mechanism of anticancer activity is also discussed. A pentadentate diamide ligand, N,N′‐di(pyridine‐2‐yl)pyridine‐2,6‐dicarboxamide (L1H2) and its tetranuclear Cu(II) complex [Cu4(L1)2(μ3‐OH)2(H2O)3(ClO4)](ClO4) ⋅ H2O are reported. X‐ray crystal structure of the complex reveals that it has an open‐book type architecture. Two central copper atoms are connected to each other by two hydroxo bridges. Each of these two hydroxo bridges also connects the two central copper atoms to one of the two terminal copper atoms. Variable temperature susceptibility measurements show that χMT decreases with the temperature, indicating a strong antiferromagnetic behavior. With the help of DFT calculations the magnetic data was analyzed using the spin Hamiltonian H=−2 J1S3 ⋅ S4 −2 J2(S3 ⋅ S1+ S3 ⋅ S2+ S4 ⋅ S1+ S4 ⋅ S2)−2 J3S1 ⋅ S2 (where subscripts 1 and 2 refer to the terminal copper atoms and 3 and 4 refer to the central copper atoms). The best fit was obtained with 2 J1=−322 cm−1, 2 J2=+34.8 cm−1, 2 J3=−8.8 cm−1 and g=2.18, indicating a δ‐type interaction between terminal copper atoms. The complex proves to be an avid binder of ct‐DNA, with apparent binding constant (Kapp) value estimated as 1.536×107 M−1. In vitro experiments indicate that the Cu(II) complex reduced the proliferation of HCT116 cells among other cell lines. This reduction of cell proliferation may be attributed to the enhancement of intracellular ROS, along with modulation and disruption of cell cycle associated proteins. SKC conceptualized the project, arranged funding and involved in overall coordination among collaborators, analyzing the data, and writing the paper. AM was involved in doing the experimental work on synthesis of the compounds, carrying out analytical and spectroscopic measurements, collecting X‐ray crystallographic data and DNA binding experiments. MS, SM and KDS were involved in study of anticancer activities of the complex. SS helped in refining X‐ray structure of the complex. MC did the magnetic measurements and analysis whereas AF did the DFT calculations.

Mixed‐Ligand Mononuclear Copper(II) Complex: Crystal Structure and Anticancer Activity

Structure and Biological Properties of Mixed-Ligand Cu(II) Schiff Base Complexes As Potential Anticancer Agents.

Synthesis, characterization and biological activity of novel copper complexes containing a β-carboline derivative and amino acids

Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.

Synthesis, crystal structure and anticancer activity of a novel ternary copper(II) complex with Schiff base derived from 2-amino-4-fluorobenzoic acid and salicylaldehyde

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

Structures and Anti-Cancer Properties of Two Binuclear Copper Complexes.

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Copper(I) Complexes With Phenanthroline‐Functionalized NHC Ligands Achieve Effective Anticancer Activity via Mitochondrial and Endoplasmic Reticulum Stress

An Asymmetric Binuclear Zinc(Ii) Complex With Mixed Iminodiacetate And Phenanthroline Ligands: Synthesis, Characterization, Structural Conversion And Anticancer Properties

A Tetranuclear copper(II) Complex with a Pyridine‐2,6‐dicarboxamide Ligand: Structural and Magnetic Properties and In vitro Antiproliferative Activity Against Human Cancer Cells

Syntheses, crystal structures of copper (II)-based complexes of sulfonamide derivatives and their anticancer effects through the synergistic effect of anti-angiogenesis, anti-inflammation, pro-apoptosis and cuproptosis

Mixed-ligand Copper(ii) Hydrazone Complexes: Synthesis, Structure, and Anti-Lung Cancer Properties

Design, Synthesis, and biological evaluation of copper(II) complexes with phenanthroline-based ligands as potential anticancer agents

DNA Binding, Crystal Structure, Molecular Docking Studies and Anticancer Activity Evaluation of a Copper(ii) Complex

Synthesis and structure elucidation of new μ-oxamido-bridged dicopper(II) complex with in vitro anticancer activity: A combined study from experiment verification and docking calculation on DNA/protein-binding property.

Copper (II) complexes based bis(pyrazolyl)borate derivatives as efficient anticancer agents: synthesis, characterization, X-ray structure, cytotoxicity, molecular docking and QSAR studies

DNA/BSA‐binding Property and in Vitro Anticancer Activity of a New Dicopper(ii) Complex with N‐(2‐hydroxy‐5‐nitrophenyl)‐N′‐[3‐(diethylamino)propyl]oxamide As Bridging Ligand: Synthesis and Crystal Structure

Square pyramidal Cu(II) Acylpyrazolone Complex: Synthesis, Characterization, Crystal structure, DFT and Hirshfeld analysis, in-vitro anti-cancer evaluation

Synthesis and Structure of A Ternary Copper(Ii) Complex with Mixed Ligands of Diethylenetriamine and Picrate: Dna/Protein-Binding Property and in Vitro Anticancer Activity Studies

Hypotoxic Copper Complexes with Potent Anti-Metastatic and Anti-Angiogenic Activities Against Cancer Cells